Phase I Trial of BAY 50-4798, an Interleukin-2–Specific Agonist in Advanced Melanoma and Renal Cancer

Kim Margolin; Michael B. Atkins; Janice P. Dutcher; Marc S. Ernstoff; John W. Smith; Joseph I. Clark; Joseph Baar; Jeffrey A. Sosman; Jeffrey S. Weber; Chetan Lathia

doi:10.1158/1078-0432.ccr-06-1341

Phase I Trial of BAY 50-4798, an Interleukin-2–Specific Agonist in Advanced Melanoma and Renal Cancer

NobleID: NI2P54W95R82S05
Persistent link: https://nobleid.org/ark:/48914/w1/20260515/D9379CCF

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/D9379CCF.svg?ark=w1%2F20260515%2FD9379CCF&value=id)](https://nobleid.org/work/w1/20260515/D9379CCF)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Phase I Trial of BAY 50-4798, an Interleukin-2–Specific Agonist in Advanced Melanoma and Renal Cancer

NobleID: NI2P54W95R82S05
Persistent link: https://nobleid.org/ark:/48914/w1/20260515/D9379CCF

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/D9379CCF.svg?ark=w1%2F20260515%2FD9379CCF&value=id)](https://nobleid.org/work/w1/20260515/D9379CCF)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work